Publications
232 results found
Vardas E, Kaleebu P, Bekker LG, et al., 2010, A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus, AIDS Res Hum Retroviruses, Vol: 26, Pages: 933-942, ISSN: 1931-8405
Spentzou A, Bergin P, Gill D, et al., 2010, Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates, J Infect Dis, Vol: 201, Pages: 720-729, ISSN: 1537-6613
Howles S, Guimaraes-Walker A, Yang H, et al., 2010, Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects, Vaccine, Vol: 28, Pages: 7306-7312, ISSN: 1873-2518
Vasan S, Hurley A, Schlesinger SJ, et al., 2009, OA05-01. In vivo electroporation enhances the immunogenicity of ADVAX, a DNA-based HIV-1 vaccine candidate, in healthy volunteers, Retrovirology, Vol: 6
- Cite
- Citations: 6
Price MA, Allen S, Anzala O, et al., 2009, P06-08. Building an African HIV preventive trial network, Retrovirology, Vol: 6
Stevens G, Chetty P, Stout J, et al., 2009, P06-07. A GCLP accredited Clinical Trial Laboratory Network in Africa and India: A collaborative effort between IAVI and in country research organizations, Retrovirology, Vol: 6
Karita E, Ketter N, Price MA, et al., 2009, CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa, PLoS One, Vol: 4, ISSN: 1932-6203
Pala P, Gomez-Roman VR, Gilmour J, et al., 2009, An African perspective on mucosal immunity and HIV-1, Mucosal Immunol, Vol: 2, Pages: 300-314, ISSN: 1935-3456
Crawford H, Lumm W, Leslie A, et al., 2009, Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients, J Exp Med, Vol: 206, Pages: 909-921, ISSN: 1540-9538
Ramanathan VD, Kumar M, Mahalingam J, et al., 2009, A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers, AIDS Res Hum Retroviruses, Vol: 25, Pages: 1107-1116, ISSN: 1931-8405
Stevens G, Chetty P, Stout J, et al., 2009, A GCLP accredited Clinical Trial Laboratory Network in Africa and India: a collaborative effort between IAVI and in country research organizations, Publisher: BIOMED CENTRAL LTD, ISSN: 1742-4690
Huang Y, Sato A, Wood B, et al., 2009, Statistical design and analysis of the CAVD-VIMC Elispot transfer study 001, Publisher: BIOMED CENTRAL LTD, ISSN: 1742-4690
Price MA, Allen S, Anzala O, et al., 2009, Building an African HIV preventive trial network, Publisher: BIOMED CENTRAL LTD, ISSN: 1742-4690
Boaz MJ, Hayes P, Tarragona T, et al., 2009, Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents, Clin Vaccine Immunol, Vol: 16, Pages: 147-155, ISSN: 1556-679X
Stevens G, Kenyon A, Molapo S, et al., 2008, Monitoring Clinical Trial Site Laboratories: The need for Comprehensive External Quality Assurance Programs, AIDS Vaccine 2008 Conference, Publisher: MARY ANN LIEBERT INC, Pages: 65-66, ISSN: 0889-2229
Gilmour J, Gill D, Huang Y, et al., 2008, Excellent Concordance between IFN-gamma ELISpot Assay Results in Two Comprehensive T Cell Vaccine Immune Monitoring Consortium (CTC-VIMC) Laboratories, AIDS Vaccine 2008 Conference, Publisher: MARY ANN LIEBERT INC, Pages: 137-137, ISSN: 0889-2229
Bergin PJ, Spentzou A, Gil D, et al., 2008, Qualification of a CD8 T-Cell Mediated, In Vitro, Viral Suppression Assay for Use in HIV Vaccine Trials, AIDS Vaccine 2008 Conference, Publisher: MARY ANN LIEBERT INC, Pages: 136-136, ISSN: 0889-2229
Mehendale S, van Lunzen J, Clumeck N, et al., 2008, A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine, AIDS Res Hum Retroviruses, Vol: 24, Pages: 873-880, ISSN: 1931-8405
Mehendale S, van Lunzen J, Clumeck N, et al., 2008, A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine, AIDS RESEARCH AND HUMAN RETROVIRUSES, Vol: 24, Pages: 873-880, ISSN: 0889-2229
- Author Web Link
- Cite
- Citations: 38
Stevens W, Kamali A, Karita E, et al., 2008, Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials, PLoS One, Vol: 3, ISSN: 1932-6203
Guimaraes-Walker A, Mackie N, McCormack S, et al., 2008, Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers, Vaccine, Vol: 26, Pages: 6671-6677, ISSN: 0264-410X
Jaoko W, Nakwagala FN, Anzala O, et al., 2008, Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa, Pages: 2788-2795, ISSN: 0264-410X
The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. Both vaccines, expressing HIV-1 subtype A gag p24/p17 and a string of CD8 T-cell epitopes (HIVA), were generally safe and well-tolerated. At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed by a validated ex vivo interferon gamma (IFN-gamma) ELISPOT assay and Cytokine Flow Cytometry (CFC), did not significantly differ from placebo recipients. These trials demonstrated the feasibility of conducting high-quality Phase 1 trials in Africa.
Fox Z, Antunes F, Davey R, et al., 2007, Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2, HIV MEDICINE, Vol: 8, Pages: 112-123, ISSN: 1464-2662
- Author Web Link
- Cite
- Citations: 7
Peters BS, Jaoko W, Vardas E, et al., 2007, Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity, Vaccine, Vol: 25, Pages: 2120-2127, ISSN: 0264-410X
Bashir F, Ogola S, Idangasi J, et al., 2007, Ensuring Good Clinical Laboratory Practice (GCLP) compliance during the conduct of HIV-1 Vaccine clinical trials at Kenya AIDS Vaccine Initiative (KAVI)., AIDS Vacinne 2007 Conference
Gilmour JW, Stevens WS, Gray C, et al., 2007, Laboratory expansion to large-scale international HIV preventive vaccine trials, Curr Opin HIV AIDS, Vol: 2, Pages: 201-206, ISSN: 1746-6318
Gotch F, Gilmour J, 2007, Science, medicine and research in the developing world: a perspective, Nat Immunol, Vol: 8, Pages: 1273-1276, ISSN: 1529-2916
Goonetilleke N, Moore S, Dally L, et al., 2006, Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes, J Virol, Vol: 80, Pages: 4717-4728, ISSN: 0022-538X
Maecker HT, Rinfret A, D'Souza P, et al., 2005, Standardization of cytokine flow cytometry assays, BMC Immunol, Vol: 6, ISSN: 1471-2172
Kebba A, Kaleebu P, Serwanga J, et al., 2004, HIV type 1 antigen-responsive CD4+ T-lymphocytes in exposed yet HIV Type 1 seronegative Ugandans, AIDS Res Hum Retroviruses, Vol: 20, Pages: 67-75, ISSN: 0889-2229
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.